Basma M Medhat1, Mervat Essam Behiry2, Nesreen Sobhy3, Yomna Farag4, Huda Marzouk4, Noha Mostafa4, Iman Khalifa5, Marwa Elkhalifa6, Basma M Eissa3, Eman Hassan ElSayed Hassan6. 1. Rheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Kasr Al Ainy St., Cairo, 11562, Egypt. basmamedhat@kasralainy.edu.eg. 2. Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt. 3. Rheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Kasr Al Ainy St., Cairo, 11562, Egypt. 4. Pediatric Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. 5. Pediatric Department, Faculty of Medicine, Helwan University, Helwan, Egypt. 6. Rheumatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Abstract
INTRODUCTION: The aim of this study was to investigate the characteristics and outcome of systemic lupus erythematosus (SLE) among elderly-onset patients. METHODS: This study included 575 SLE patients managed at Cairo, Alexandria, and Helwan universities from August 2014 to 2018: of whom 49 (8.5%), 420 (73%), and 106 (18.4%) were elderly- (> 50 years), adult- (17-50 years), and juvenile- (≤ 16 years) onset patients, respectively. Cumulative characteristics were recorded. Disease activity at the last visit was investigated through the Systemic Lupus Erythematosus Disease Activity Index-2K (SLEDAI-2K), whereby lupus low disease activity (LLDA) was defined as a SLEDAI-2K score ≤ 4. The disease outcome was assessed through investigating disease damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)) and the prevalence of mortality. Quantitative and categorical data were compared using Kruskal-Wallis and Mann-Whitney tests, and chi-square (χ2) test, respectively. RESULTS: Late-onset SLE (LSLE) patients demonstrated the lowest prevalence of constitutional and mucocutaneous manifestations (p < 0.001), serositis (p = 0.006), nephritis (p < 0.001), neuropsychiatric involvement (p < 0.001), and hypocomplementinemia (p < 0.001), but showed the highest prevalence of comorbidities and multimorbidity (comorbidities ≥ 2) (p < 0.001), and positive anti-ds DNA antibodies (p < 0.001). Elderly-onset patients demonstrated the lowest SLEDAI-2K and SDI scores, achieved LLDA the most (p < 0.001), and developed any damage (SDI ≥ 1) the least (p < 0.001). The prevalence of mortality was comparable across the three age groups (p = 0.6). CONCLUSIONS: Late-onset SLE patients (8.5%) showed the lowest prevalence of major organ involvement and the highest prevalence of comorbidities, and demonstrated more favorable disease activity and damage indices.Key Points• The disease characteristics and outcome among LSLE patients are characterized by being controversial, with studies from the Middle East being limited. Our cohort constituted of 8.5% elderly-onset SLE patients-who were characterized by the lowest prevalence of major organ involvement and the lowest activity and damage indices-making the disease pattern more favorable in this age group, despite being characterized by the highest prevalence of comorbidities.
INTRODUCTION: The aim of this study was to investigate the characteristics and outcome of systemic lupus erythematosus (SLE) among elderly-onset patients. METHODS: This study included 575 SLE patients managed at Cairo, Alexandria, and Helwan universities from August 2014 to 2018: of whom 49 (8.5%), 420 (73%), and 106 (18.4%) were elderly- (> 50 years), adult- (17-50 years), and juvenile- (≤ 16 years) onset patients, respectively. Cumulative characteristics were recorded. Disease activity at the last visit was investigated through the Systemic Lupus Erythematosus Disease Activity Index-2K (SLEDAI-2K), whereby lupus low disease activity (LLDA) was defined as a SLEDAI-2K score ≤ 4. The disease outcome was assessed through investigating disease damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)) and the prevalence of mortality. Quantitative and categorical data were compared using Kruskal-Wallis and Mann-Whitney tests, and chi-square (χ2) test, respectively. RESULTS: Late-onset SLE (LSLE) patients demonstrated the lowest prevalence of constitutional and mucocutaneous manifestations (p < 0.001), serositis (p = 0.006), nephritis (p < 0.001), neuropsychiatric involvement (p < 0.001), and hypocomplementinemia (p < 0.001), but showed the highest prevalence of comorbidities and multimorbidity (comorbidities ≥ 2) (p < 0.001), and positive anti-ds DNA antibodies (p < 0.001). Elderly-onset patients demonstrated the lowest SLEDAI-2K and SDI scores, achieved LLDA the most (p < 0.001), and developed any damage (SDI ≥ 1) the least (p < 0.001). The prevalence of mortality was comparable across the three age groups (p = 0.6). CONCLUSIONS: Late-onset SLE patients (8.5%) showed the lowest prevalence of major organ involvement and the highest prevalence of comorbidities, and demonstrated more favorable disease activity and damage indices.Key Points• The disease characteristics and outcome among LSLE patients are characterized by being controversial, with studies from the Middle East being limited. Our cohort constituted of 8.5% elderly-onset SLE patients-who were characterized by the lowest prevalence of major organ involvement and the lowest activity and damage indices-making the disease pattern more favorable in this age group, despite being characterized by the highest prevalence of comorbidities.
Authors: R Cervera; A Doria; Z Amoura; M Khamashta; M Schneider; F Guillemin; F Maurel; A Garofano; M Roset; A Perna; M Murray; C Schmitt; I Boucot Journal: Autoimmun Rev Date: 2014-01-10 Impact factor: 9.754
Authors: Jacques Boddaert; Du Le Thi Huong; Zahir Amoura; Bertrand Wechsler; Pierre Godeau; Jean-Charles Piette Journal: Medicine (Baltimore) Date: 2004-11 Impact factor: 1.889
Authors: L J Catoggio; E R Soriano; P M Imamura; D Wojdyla; S Jacobelli; L Massardo; R Chacón Díaz; M Guibert-Toledano; A Alvarellos; V Saurit; J A Manni; V Pascual-Ramos; A W Silva de Sauza; E Bonfa; J C Tavares Brenol; L A Ramirez; L A Barile-Fabris; I Garcia De La Torre; G S Alarcón; B A Pons-Estel Journal: Lupus Date: 2014-12-11 Impact factor: 2.911
Authors: X Feng; Y Zou; W Pan; X Wang; M Wu; M Zhang; J Tao; Y Zhang; K Tan; J Li; Z Chen; X Ding; X Qian; Z Da; M Wang; L Sun Journal: Lupus Date: 2013-12-02 Impact factor: 2.911
Authors: R Cervera; M A Khamashta; J Font; G D Sebastiani; A Gil; P Lavilla; I Doménech; A O Aydintug; A Jedryka-Góral; E de Ramón Journal: Medicine (Baltimore) Date: 1993-03 Impact factor: 1.889